12:46 PM EST, 12/09/2024 (MT Newswires) -- CRISPR Therapeutics ( CRSP ) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.

Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.

"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol," the company said.

CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Price: 50.78, Change: -1.55, Percent Change: -2.97